Cell And Gene Therapy (CGT) Scheduling Software Market Report 2026

Cell And Gene Therapy (CGT) Scheduling Software Market Overview

• Cell And Gene Therapy (CGT) Scheduling Software market size has reached to $0.32 billion in 2025 • Expected to grow to $0.8 billion in 2030 at a compound annual growth rate (CAGR) of 19.7% • Growth Driver: Growing Demand For Personalized Medicine Driving The Market Growth Due To Advances In Genomic Technologies And Molecular Diagnostics • Market Trend: Unified Digital Orchestration Platforms Transform Advanced Therapy Scheduling And Coordination • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cell And Gene Therapy (CGT) Scheduling Software Market?

Cell and gene therapy (CGT) scheduling software refers to specialized digital solutions designed to manage and optimize the complex scheduling, tracking, and coordination of cell and gene therapy treatments, including patient appointments, laboratory processes, and manufacturing timelines. This software ensures timely administration, regulatory compliance, and efficient resource utilization across clinical and manufacturing workflows in CGT operations. The main components of cell and gene therapy (CGT) scheduling software include software and services. Software refers to platforms that manage and optimize scheduling, resource allocation, and workflow coordination for cell and gene therapy processes. They are provided in cloud-based and on-premises deployment models. The key applications of cell therapy, gene therapy, tissue engineering, and other applications, while the end-use includes pharmaceutical companies, biotechnology companies, research institutes, hospitals and clinics, and other end-users.

What Is The Cell And Gene Therapy (CGT) Scheduling Software Market Growth Forecast?

The cell and gene therapy (CGT) scheduling software market size is expected to see rapid growth in the next few years. It will grow to $0.8 billion in 2030 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to growing deployment of AI-enabled scheduling platforms, increasing integration with cloud-based CGT systems, rising demand for automated workflow and resource management, expansion of tissue engineering applications, increasing need for predictive analytics in therapy administration. Major trends in the forecast period include increasing adoption of cloud-based cgt scheduling software, rising demand for integrated workflow management solutions, growing focus on real-time supply chain coordination, expansion of regulatory compliance and reporting tools, rising implementation of training and support services.

Global Cell And Gene Therapy (CGT) Scheduling Software Market Segmentation

1) By Component: Software, Services 2) By Deployment Mode: Cloud-Based, On-Premises 3) By Application: Cell Therapy, Gene Therapy, Tissue Engineering, Other Applications 4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Hospitals And Clinics, Other End-Users Subsegments: 1) By Software: Cloud-Based Software, On-Premises Software, Integrated Scheduling Platforms, Workflow Management Software, Supply Chain Coordination Software 2) By Services: Implementation Services, Integration Services, Consulting Services, Training And Support Services, Maintenance Services

What Is The Driver Of The Cell And Gene Therapy (CGT) Scheduling Software Market?

The growing demand for personalized medicine is expected to propel the growth of the cell and gene therapy (CGT) scheduling software market going forward. Personalized medicine refers to medical treatments and therapies tailored to individual patients based on their genetic makeup, biomarkers, and specific disease characteristics. The demand for personalized medicine is rising due to advances in genomic technologies and molecular diagnostics, which allow doctors to tailor treatments specifically to a patient’s genetic profile and improve therapeutic outcomes. Cell and gene therapy (CGT) scheduling software enhances personalized medicine by streamlining the coordination of patient-specific manufacturing, treatment timelines, and clinical workflows, ensuring timely, precise, and individualized therapy delivery tailored to each patient’s unique genetic profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, including seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is driving the growth of the cell and gene therapy (CGT) scheduling software industry.

Key Players In The Global Cell And Gene Therapy (CGT) Scheduling Software Market

Major companies operating in the cell gene therapy (CGT) scheduling software market are market are Siemens AG, Deloitte Touche Tohmatsu Limited, Thermo Fisher Scientific Inc., GE Digital LLC, SAP SE, Rockwell Automation Inc., Dassault Systèmes SE, Infor Inc., Aspen Technology Inc., Azenta Life Sciences, Kinaxis Inc., QAD Inc., Bullhorn Inc., Cryoport Inc., MasterControl Inc., TrakCel Ltd., Bluecrux NV, MangoGem S.A., Title21 Health Solutions Inc, Vineti Inc.

Global Cell And Gene Therapy (CGT) Scheduling Software Market Trends and Insights

Major companies operating in the cell and gene therapy (CGT) scheduling software markets are focusing on developing innovative solutions, such as unified digital orchestration platforms, to streamline complex therapy scheduling, enhance real-time supply chain visibility, and improve coordination between manufacturers and healthcare providers. Unified digital orchestration platforms are integrated software systems that coordinate and automate complex workflows such as patient scheduling, manufacturing slots, logistics tracking, and clinical site communication within a single centralized environment. For instance, in November 2025, TrakCel Ltd., a UK-based advanced therapy supply chain technology company, launched Cell And Gene Therapy (CGT) Gateway, a digital orchestration platform designed to streamline access to cell and gene therapies for healthcare providers. This platform is a configurable, cloud-based solution that connects treatment centers, manufacturers, and logistics partners within a single digital ecosystem, enabling automated referral management, patient onboarding, and scheduling workflows. The platform enhances transparency through real-time tracking and milestone notifications, supports regulatory compliance with secure data management features, and reduces administrative burden by digitizing communication and documentation processes. It is designed to accelerate therapy access, improve coordination across stakeholders, and minimize delays in time-sensitive autologous and allogeneic treatments.

What Are Latest Mergers And Acquisitions In The Cell And Gene Therapy (CGT) Scheduling Software Market?

In March 2023, TrakCel Ltd, a UK-based company that specialized in software for the cell and gene therapy (CGT) sector that includes robust patient scheduling capabilities, completed an integration milestone with Lonza to combine CGT manufacturing and orchestration solutions. This collaboration aims to streamline cell and gene therapy production and supply chain management by integrating TrakCel’s OCELLOS (orchestration of cell and gene therapy logistics and lifecycle operations software) with Lonza’s MODA-ES (modular open digital architecture enterprise solution) manufacturing execution system, enabling seamless data exchange, enhanced chain of identity and chain of custody tracking, and improved operational visibility. Lonza Group AG is a Switzerland-based contract development and manufacturing organization specializing in biologics manufacturing, cell and gene therapy production, and advanced pharmaceutical development services.

Regional Insights

North America was the largest region in the cell and gene therapy (CGT) scheduling software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cell And Gene Therapy (CGT) Scheduling Software Market?

The cell and gene therapy (CGT) scheduling software market includes revenues earned by entities through implementation and integration services, cloud hosting and managed services, consulting and customization, and maintenance, support, and training services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Cell And Gene Therapy (CGT) Scheduling Software Market Report 2026?

The cell and gene therapy (cgt) scheduling software market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy (cgt) scheduling software industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.